Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Borchert

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Ophthalmic Plastic and Reconstructive Surgery|July 6, 2023
Re: "Functional Versus Anatomical Forms of Nasolacrimal Duct Obstruction: Differences in Severity, Symptoms, and Quality of Life"Samuel D Browning, Grace A Borchert, Michele Y Fu, et al.
Cancer Research|December 1, 1989
Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activityD Goldstein, J A Sosman, J A Hank, et al.
Cancer Investigation|January 1, 1991
Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinomaJ A Sosman, J A Hank, K H Moore, et al.
Cancer|December 15, 1990
The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2M R Albertini, J A Sosman, J A Hank, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1997
Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patientsM R Albertini, J A Hank, J H Schiller, et al.
Respiratory Care|February 3, 2021
Implementing a Weaning Protocol for Noninvasive Respiratory Support in Neonates Decreases Overuse and Length of StayDavid N Matlock, Sarah M Perez, Heather A Borchert, et al.
Clinical Kidney Journal|July 11, 2024
Association of retinal age gap with chronic kidney disease and subsequent cardiovascular disease sequelae: a cross-sectional and longitudinal study from the UK BiobankGuanrong Wu, Xiayin Zhang, Grace A Borchert, et al.
International Ophthalmology|May 28, 2025
The spatulated glass rod: low-tech instrument for high-impact ophthalmic diagnosis and treatmentMichelle Bai, Michele Y Fu, Grace A Borchert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1996
Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB studyJ H Schiller, J A Hank, M Khorsand, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1993
A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancerC Gambacorti-Passerini, J A Hank, M R Albertini, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Ophthalmic Plastic and Reconstructive Surgery|July 6, 2023
Re: "Functional Versus Anatomical Forms of Nasolacrimal Duct Obstruction: Differences in Severity, Symptoms, and Quality of Life"Samuel D Browning, Grace A Borchert, Michele Y Fu, et al.
Cancer Research|December 1, 1989
Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activityD Goldstein, J A Sosman, J A Hank, et al.
Cancer Investigation|January 1, 1991
Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinomaJ A Sosman, J A Hank, K H Moore, et al.
Cancer|December 15, 1990
The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2M R Albertini, J A Sosman, J A Hank, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1997
Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patientsM R Albertini, J A Hank, J H Schiller, et al.
Respiratory Care|February 3, 2021
Implementing a Weaning Protocol for Noninvasive Respiratory Support in Neonates Decreases Overuse and Length of StayDavid N Matlock, Sarah M Perez, Heather A Borchert, et al.
Clinical Kidney Journal|July 11, 2024
Association of retinal age gap with chronic kidney disease and subsequent cardiovascular disease sequelae: a cross-sectional and longitudinal study from the UK BiobankGuanrong Wu, Xiayin Zhang, Grace A Borchert, et al.
International Ophthalmology|May 28, 2025
The spatulated glass rod: low-tech instrument for high-impact ophthalmic diagnosis and treatmentMichelle Bai, Michele Y Fu, Grace A Borchert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1996
Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB studyJ H Schiller, J A Hank, M Khorsand, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1993
A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancerC Gambacorti-Passerini, J A Hank, M R Albertini, et al.
Pageof 5